Compare LCII & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCII | ACAD |
|---|---|---|
| Founded | 1956 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 4.6B |
| IPO Year | N/A | 2004 |
| Metric | LCII | ACAD |
|---|---|---|
| Price | $121.06 | $27.04 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 22 |
| Target Price | ★ $102.40 | $29.05 |
| AVG Volume (30 Days) | 281.6K | ★ 1.4M |
| Earning Date | 10-30-2025 | 11-05-2025 |
| Dividend Yield | ★ 3.78% | N/A |
| EPS Growth | 38.80 | ★ 98.53 |
| EPS | ★ 7.12 | 1.54 |
| Revenue | ★ $3,992,455,000.00 | $1,047,118,000.00 |
| Revenue This Year | $10.55 | $15.16 |
| Revenue Next Year | $4.21 | $11.42 |
| P/E Ratio | ★ $17.09 | $17.62 |
| Revenue Growth | 5.74 | ★ 12.69 |
| 52 Week Low | $72.31 | $13.40 |
| 52 Week High | $122.53 | $27.73 |
| Indicator | LCII | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 70.92 | 69.78 |
| Support Level | $112.55 | $26.38 |
| Resistance Level | $118.26 | $27.73 |
| Average True Range (ATR) | 3.09 | 0.83 |
| MACD | 0.27 | 0.14 |
| Stochastic Oscillator | 86.86 | 88.00 |
LCI Industries Inc supplies domestically and internationally components for the original equipment manufacturers of recreational vehicles and adjacent industries including buses; and trailers used to haul boats, livestock, equipment, and other cargo. It has two reportable segments; the original equipment manufacturers segment and the aftermarket segment. The OEM Segment manufactures or distributes components for the OEMs of RVs and adjacent industries, including buses; trailers used to haul boats, livestock, equipment, and other cargo; trucks; pontoon boats; trains; manufactured homes; and modular housing. Its products are sold to manufacturers of RVs such as Thor Industries, Forest River, Winnebago, and other RV OEMs, and to manufacturers in adjacent industries.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.